Failed biotechs tout cash to attract buyers
BOSTON (Reuters) - Small biotechnology companies with cash but failed or floundering products are in hot demand as partners for companies that are unable to raise money in the capital markets.
<p><img src="http://feeds.reuters.com/~a/reuters/scienceNews?i=hGyoxH" border="0"></img> (http://feeds.reuters.com/~a/reuters/scienceNews?a=hGyoxH)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/scienceNews?i=Awh3L" border="0"></img> (http://feeds.reuters.com/~f/reuters/scienceNews?a=Awh3L) <img src="http://feeds.reuters.com/~f/reuters/scienceNews?i=qPskl" border="0"></img> (http://feeds.reuters.com/~f/reuters/scienceNews?a=qPskl) <img src="http://feeds.reuters.com/~f/reuters/scienceNews?i=rMZIl" border="0"></img> (http://feeds.reuters.com/~f/reuters/scienceNews?a=rMZIl)
</div><img src="http://feeds.reuters.com/~r/reuters/scienceNews/~4/402799916" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/scienceNews/~3/402799916/idUSTRE48O4A020080925